183 related articles for article (PubMed ID: 9717829)
1. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control.
Pollock R; Lang A; Ge T; Sun D; Tan M; Yu D
Clin Cancer Res; 1998 Aug; 4(8):1985-94. PubMed ID: 9717829
[TBL] [Abstract][Full Text] [Related]
2. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity.
Milas M; Yu D; Lang A; Ge T; Feig B; El-Naggar AK; Pollock RE
Cancer Gene Ther; 2000 Mar; 7(3):422-9. PubMed ID: 10766348
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells.
David-Pfeuty T; Chakrani F; Ory K; Nouvian-Dooghe Y
Cell Growth Differ; 1996 Sep; 7(9):1211-25. PubMed ID: 8877102
[TBL] [Abstract][Full Text] [Related]
5. [Effects of exogenous wild type p53 on malignant growth of human lung cancer cell line].
Wang H; Lai B; Li J
Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):268-72. PubMed ID: 11326947
[TBL] [Abstract][Full Text] [Related]
6. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression.
Zhan M; Yu D; Lang A; Li L; Pollock RE
Cancer; 2001 Sep; 92(6):1556-66. PubMed ID: 11745235
[TBL] [Abstract][Full Text] [Related]
7. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Cherney BW; Bhatia KG; Sgadari C; Gutierrez MI; Mostowski H; Pike SE; Gupta G; Magrath IT; Tosato G
Cancer Res; 1997 Jun; 57(12):2508-15. PubMed ID: 9192833
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status.
Milas M; Yu D; Sun D; Pollock RE
Clin Cancer Res; 1998 Jun; 4(6):1573-9. PubMed ID: 9626480
[TBL] [Abstract][Full Text] [Related]
9. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of p53 with deletion of c-terminal 356 - 393 amino acids on malignant phenotype of human lung cancer cell line].
Wang H; Li JZ; Lai BT; Yang XH; Zhang CY; Yue WT; Zhan XP
Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):527-30. PubMed ID: 14690553
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Cell Mol Biol Lett; 2001; 6(2):117-40. PubMed ID: 11544635
[TBL] [Abstract][Full Text] [Related]
12. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53.
St John LS; Sauter ER; Herlyn M; Litwin S; Adler-Storthz K
Cancer Gene Ther; 2000 May; 7(5):749-56. PubMed ID: 10830722
[TBL] [Abstract][Full Text] [Related]
13. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
Ling YH; Zou Y; Perez-Soler R
Anticancer Res; 2000; 20(2A):693-702. PubMed ID: 10810342
[TBL] [Abstract][Full Text] [Related]
14. Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro growth characteristics of the AA/C1 human adenoma derived cell line, including sensitivity to transforming growth factor-beta 1.
Williams AC; Browne SJ; Manning AM; Daffada P; Collard TJ; Paraskeva C
Oncogene; 1994 May; 9(5):1479-85. PubMed ID: 8152811
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
16. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53.
Qazilbash MH; Xiao X; Seth P; Cowan KH; Walsh CE
Gene Ther; 1997 Jul; 4(7):675-82. PubMed ID: 9282168
[TBL] [Abstract][Full Text] [Related]
17. Stable expression of temperature-sensitive p53: a suitable model to study wild-type p53 function in pancreatic carcinoma cells.
Nuevemann D; Christgen M; Ungefroren H; Kalthoff H
Oncol Rep; 2006 Sep; 16(3):575-9. PubMed ID: 16865258
[TBL] [Abstract][Full Text] [Related]
18. p53-mediated regulation of cell cycle progression: pronounced impact of cellular microenvironment.
Schmid G; Kramer MP; Wesierska-Gadek J
J Cell Physiol; 2009 May; 219(2):459-69. PubMed ID: 19170070
[TBL] [Abstract][Full Text] [Related]
19. Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells.
Lang D; Miknyoczki SJ; Huang L; Ruggeri BA
Oncogene; 1998 Mar; 16(12):1593-602. PubMed ID: 9569027
[TBL] [Abstract][Full Text] [Related]
20. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo.
Rubio R; García-Castro J; Gutiérrez-Aranda I; Paramio J; Santos M; Catalina P; Leone PE; Menendez P; Rodríguez R
Cancer Res; 2010 May; 70(10):4185-94. PubMed ID: 20442289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
